Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Andre, F.
Right arrow Articles by Soria, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andre, F.
Right arrow Articles by Soria, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:3-4, 2004
© 2004 European Society for Medical Oncology

Her2-neu: a target in lung cancer?

F. Andre, T. Le Chevalier and J. C. Soria

Department of Medicine, Institut Gustave Roussy, Villejuif, France

The first 10% of the full text of this article appears below.

In addition to the steady flow of new cytotoxic drugs for lung cancer during the last decade, the elegant concept of targeted agents has in recent years become a source of optimism and pitfalls. Among all the targets, Her2-neu is a typical example of how preclinical data can be translated into clinical progress.

Her2-neu in breast cancer: the ideal model

Erb-B2 (Her2-neu) is a 185 kDa glycoprotein with tyrosine kinase activity. This protein is a member of the ErbB receptor family that also includes ErbB1 (EGFr), ErbB3 and ErbB4. The implication of Her2-neu in mammary carcinogenesis has been shown in vitro [1] and in vivo [2]. Since then, most of the studies focusing on ErbB2 have been carried out in breast cancer. In this model, it has been shown that ErbB2 overexpression was associated . . . [Full Text of this Article]

Her2-neu in lung cancer: is the mammalian model adequate in bronchial tumors?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. J. Kerr
Concordia res parvae crescent
Ann. Onc., January 1, 2006; 17(1): 3 - 4.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr
Teenage kicks
Ann. Onc., January 1, 2005; 16(1): 1 - 2.
[Full Text] [PDF]